Moderna Inc

MRNA: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
LOCK|m>LOCK|CySLOCK|&%sH#&

Moderna: Analyst Day Supports Our Bullish Oncology Call; Pruned Pipeline Helps Conserve Cash

Moderna held an analyst day on Nov. 20, where it made several announcements, including a new $1.5 billion credit facility, expectations for up to 10% revenue growth in 2026, improving gross margins through 2028, and discontinuations of midstage shingles and herpes programs. Shares fell 7%.

Sponsor Center